Madrigal Pharmaceuticals, Inc. (MDGL) Declines Again; Strong Momentum for Sellers

The stock of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a huge mover today! The stock decreased 6.06% or $6.11 during the last trading session, reaching $94.71. About 254,884 shares traded or 41.81% up from the average. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has declined 66.44% since September 13, 2018 and is downtrending. It has underperformed by 66.44% the S&P500.
The move comes after 9 months negative chart setup for the $1.46 billion company. It was reported on Sep, 13 by We have $89.97 PT which if reached, will make NASDAQ:MDGL worth $73.05M less.

Analysts await Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report earnings on November, 5. They expect $-1.36 EPS, down 142.86 % or $0.80 from last year’s $-0.56 per share. After $-1.28 actual EPS reported by Madrigal Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 6.25 % negative EPS growth.

More notable recent Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news were published by: which released: “Here’s Why Madrigal Pharmaceuticals Fell 39.4% in November – The Motley Fool” on December 08, 2018, also with their article: “Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy? – Yahoo Finance” published on May 01, 2019, published: “Madrigal And Resmetirom In NASH: Killing Liver Fat – Seeking Alpha” on April 16, 2019. More interesting news about Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) were released by: and their article: “Madrigal Pharmaceuticals Enters Oversold Territory (MDGL) – Nasdaq” published on April 22, 2019 as well as‘s news article titled: “Madrigal: Weighed Down By Relevant Concerns Heading Into Pivotal Data – Seeking Alpha” with publication date: July 31, 2019.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.46 billion. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.